Search
Subscribe
-
Latest Tweets
2/ assume pre-seed of 1.5M on 10M post - 15% dilution + seed of 4M for another 15% - 26M post OK so we’ve got two… https://t.co/kfgQhXAOeD - 6 seconds ago
1/ I need your opinion on something VC related. Series A investor is adamant that any dilution from pre-seed and… https://t.co/txAmepA1IR - 8 minutes ago
Productising VC is hard. Founders don’t need how-to-guides. They rarely need operational help, or can get it else… https://t.co/ANm4KTHoJu - 4 hours ago
@Evanish It’s also hilarious as there are 5 people in there - 13 hours ago
@pjozefak @gdibner + No pressure to exit + Continuity of investors / BMs - they own you - 13 hours ago
-
Recent Posts
-
Jul 9
VC Signalling Risk in Seed Rounds -
Jun 3
Pillpack: Adding $50M in funding to bring redesigned pharmacy to all -
Feb 17
Developing London tech clusters beyond Shoreditch: Croydon ? -
Oct 2
Cytokinesis at Atlas Venture: bio and tech take off -
May 19
Zoopla at seven – how focus and speed drive exceptional outcomes
Notable Posts
-
Jul 9
Author Archives: freddestin
VC Signalling Risk in Seed Rounds
CB Insights just published an interesting post about signalling risk i.e. the startup survival risk generated by getting a Tier I VC into the seed round who does not follow their money into the Series A. The data suggests getting no …
Comments Off on VC Signalling Risk in Seed Rounds
Pillpack: Adding $50M in funding to bring redesigned pharmacy to all
There are some people in the world that it is simply a joy to work with, and when good things happened to them you can only feel joy. TJ Parker and Elliott Cohen are two such people and I’m delighted …
Comments Off on Pillpack: Adding $50M in funding to bring redesigned pharmacy to all
Developing London tech clusters beyond Shoreditch: Croydon ?
Here in London we’re all very proud of the progress made over the last few years. Having come back from 4 years in Boston, I have been surprised by the level of maturity that we have achieved and how far …
Cytokinesis at Atlas Venture: bio and tech take off
Atlas Venture announced at his latest annual meeting that the biotech and tech groups were going their own way. Since I did spend ten years there, let me give you my view on it. Aligned, yet different The two groups …
Comments Off on Cytokinesis at Atlas Venture: bio and tech take off
Zoopla at seven – how focus and speed drive exceptional outcomes
I first invested in Zoopla in July 2007. At the time, a mere £500,000 to get the company going and back Simon Kain and Alex Chesterman in improving the real estate experience. Last week, almost exactly 7 years after this …
The Boston Surprise
Now that I am leaving Boston I can talk about its startup ecosystem in all candor. When I came over 4 years ago, it was essentially as an act of belief in my partner Jeff and in myself. To …
Why Series B is usually the hardest
Tom Tunguz and Danielle Morrill both came out with data suggesting Series B are hard. Tom calls it the “hardest round to raise”, based on his numbers. Let me try to address why that is. Let’s assume we’re in …
Pro-rata rights: the good, the bad and the ugly
Fred Wilson posted an article to explain the concept and value of pro-rata rights, with his usual elegance in making the concept clear. Pro-rata rights are incredibly valuable for a simple reason: most startup companies fail, but pro-rata rights are …
How we can thrive in a world of Chaos
Late last year I gave a TEDx talk about “thriving in a world of chaos”, looking at how we can deal with a level of unpredictability and a speed of change we were not genetically designed for and searching for …
Backing PillPack : a pharmacy you might actually love
Pharmacies are like banks. When you have to go to one, it’s usually an unpleasant experience delivered in often indifferent fashion by overworked people. TJ Parker and Elliott Cohen, the founders of Pillpack, together with the rest of the team, …